Effect of Heparin on Blood Vascular Endothelial Growth Factor Levels in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

American Journal of Cardiology

Volumn 98, Issue 7, 2006, Pages 902-905

  Pyda, Małgorzata ^a   Korybalska, Katarzyna ^a   Ksia̧zek, Krzysztof ^a   Grajek, Stefan ^a   Łanocha, Magdalena ^a   Lesiak, Maciej ^a   Wiśniewska Elnur, Justyna ^a   Olasińska, Anna ^a   Brȩborowicz, Andrzej ^a   Cieśliński, Andrzej ^a   Witowski, Janusz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; VASCULOTROPIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM CELL; FEMALE; HUMAN; INCUBATION TIME; INFUSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CASE-CONTROL STUDIES; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33748753262     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.04.028     Document Type: Article

References (16)

1. Lee S.H., Wolf P.L., Escudero R., Deutsch R., Jamieson S.W., and Thistlethwaite P.A. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 342 (2000) 626-633
2. Heeschen C., Dimmeler S., Hamm C.W., Boersma E., Zeiher A.M., and Simoons M.L. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 107 (2003) 524-530
3. Kawamoto A., Kawata H., Akai Y., Katsuyama Y., Takase E., Sasaki Y., Tsujimura S., Sakaguchi Y., Iwano M., Fujimoto S., et al. Serum levels of VEGF and basic FGF in the subacute phase of myocardial infarction. Int J Cardiol 67 (1998) 47-54
4. Kranz A., Rau C., Kochs M., and Waltenberger J. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J Mol Cell Cardiol 32 (2000) 65-72
5. Ogawa H., Suefuji H., Soejima H., Nishiyama K., Misumi K., Takazoe K., Miyamoto S., Kajiwara I., Sumida H., Sakamoto T., et al. Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. Cardiology 93 (2000) 93-99
6. Seko Y., Fukuda S., and Nagai R. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy. Clin Sci (Lond) 106 (2004) 439-442
7. Soeki T., Tamura Y., Shinohara H., Tanaka H., Bando K., and Fukuda N. Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels 15 (2000) 105-111
8. Soeki T., Tamura Y., Shinohara H., Tanaka H., Bando K., and Fukuda N. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology 93 (2000) 168-174
9. East M.A., Landis D.I., Thompson M.A., and Annex B.H. Effect of single dose of intravenous heparin on plasma levels of angiogenic growth factors. Am J Cardiol 91 (2003) 1234-1236
10. Bhatia L., Clesham G.J., and Turner D.R. Effect of intravenous heparin on serum levels of endostatin, VEGF and HGF. Clin Sci (Lond) 107 (2004) 423
11. Edgell C.J., McDonald C.C., and Graham J.B. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 80 (1983) 3734-3737
12. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47 (2001) 617-623
13. Webb N.J., Bottomley M.J., Watson C.J., and Brenchley P.E. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 94 (1998) 395-404
14. Hirsh J., Anand S.S., Halperin J.L., and Fuster V. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation 103 (2001) 2994-3018
15. Chan A.K., Paredes N., Thong B., Chindemi P., Paes B., Berry L.R., and Monagle P. Binding of heparin to plasma proteins and endothelial surfaces is inhibited by covalent linkage to antithrombin. Thromb Haemost 91 (2004) 1009-1018
16. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., and De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56 (2004) 549-580